A challenge that anyone working to bring new technology, therapies, or approaches from proof of concept to clinic implementation is funding. I have been tracking the concept of crowd funding for a number of years, but have not seen many platforms that offer the opportunity to raise funding to a degree that will really make a difference.
So, I was enthusiastic when I met Pilar Puig Sàrries and learned about the work she is doing at Capital Cell, a crowdfunding platform specializing in the life sciences. She is the head the BioExpert Network and life sciences analytics at Capital Cell and passionate about her work to help startups in the life sciences bridge the translational gap.
How did you start doing what you are doing now?
During my PhD in molecular biology I felt uncertain about becoming a Spanish researcher because in Spain every 1-3 years you need to apply for further support for your research which means no stability.
So, during my PhD I began my first startup. It was an online/offline game for couples. I was able to sell 1.000 games after closing a successful crowdfunding campaign, which in my mind was pretty successful. But I also had to write my thesis and I also had a big interest in travel.
After my PhD I took a 9 month trip to South America and those 9 months were the happiest time of my life. When I came back, I knew that I didn’t want to keep doing research, so it seemed ideal to do something related to science, but also related to entrepreneurship. I was fortunate to find an opportunity at Capital Cell as a life science analyst.
What do you do at Capital Cell?
Capital cell is a start-up which means anyone working there has many roles. My job title is life science analyst, but I also do business development for clients such as helping them with their business models and building their pitch. We also help them look for investors as well. I also produce content for the website. Last year with the CEO of Capital Cell we created the BioExpert Network which is a network of experts who help us evaluate and select companies to be included in our crowdfunding platform.
Can you explain a bit about the philosophy behind Capital Cell and how it works?
Capital Cell is the first equity crowdfunding specialized in life sciences in Europe. And since last September, we are also operating in the UK.
We help companies in the life science sector get funded. Most of them are in the ‘valley of death’, which is also called the translational gap. They may have proof of concept, but need capital to continue to get scientific validation. We are now working with some companies that are further along, but still need to have some more funding before approaching VCs.
Image Credit: Shutterstock.com
News This Week
Nature wades through the literature on the new coronavirus — and summarizes key papers as they appear: 1 June — Positive coronavirus test is no guarantee of infectiousness People with COVID-19 are unlikely to [...]
In April, blood clots emerged as one of the many mysterious symptoms attributed to Covid-19, a disease that had initially been thought to largely affect the lungs in the form of pneumonia. Quickly after came [...]
Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay [...]
Rheumatologists at the University of Alberta are flagging similarities between the deaths of some COVID-19 patients and those with rheumatic illnesses, and are testing proven rheumatic treatments to see whether they help against [...]
Next-gen nano technologies that can prevent infection and diagnose disease are set to transform the medical industry as this important UniSA research is awarded more than $2 million dollars under the National Health and [...]
In late December last year, Dr. Li Wenliang began warning officials about a novel coronavirus in Wuhan, China, but was silenced by the police before tragically succumbing to the disease two months later. Meanwhile, [...]
Almost 10 weeks into the pandemic, COVID-19 is continuing to surprise and baffle health experts. In fact, experts' picture of exactly how COVID-19 might play out in the body is now quite different to [...]
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines. This approach opens the possibility to engineer safer and more effective vaccines. Vaccines [...]